OBI Pharma, Inc. (4174.TWO)
TWD 55.8
(-10.0%)
TWD 55.8
(-10.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -73.49 Million TWD | -83.08% |
| 2022 | -40.14 Million TWD | -56.87% |
| 2021 | -25.59 Million TWD | -119.04% |
| 2020 | 134.41 Million TWD | 159.62% |
| 2019 | -225.45 Million TWD | -2899.64% |
| 2018 | 8.05 Million TWD | 112.04% |
| 2017 | -66.89 Million TWD | -242.35% |
| 2016 | 46.99 Million TWD | 240.57% |
| 2015 | -33.43 Million TWD | 0.0% |
| 2014 | - TWD | 0.0% |
| 2013 | - TWD | 0.0% |
| 2012 | - TWD | 0.0% |
| 2011 | - TWD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -67.94 Million TWD | 14.49% |
| 2024 Q1 | -79.46 Million TWD | -459.22% |
| 2024 Q3 | -15.07 Million TWD | 77.81% |
| 2023 Q3 | -21.46 Million TWD | -15.38% |
| 2023 Q4 | -14.2 Million TWD | 33.79% |
| 2023 FY | -73.49 Million TWD | -83.08% |
| 2023 Q1 | -19.22 Million TWD | -135.03% |
| 2023 Q2 | -18.6 Million TWD | 3.27% |
| 2022 FY | -40.14 Million TWD | -56.87% |
| 2022 Q3 | -8.14 Million TWD | 32.97% |
| 2022 Q1 | -11.66 Million TWD | 5.72% |
| 2022 Q2 | -12.15 Million TWD | -4.17% |
| 2022 Q4 | -8.18 Million TWD | -0.43% |
| 2021 Q4 | -12.37 Million TWD | -346.68% |
| 2021 FY | -25.59 Million TWD | -119.04% |
| 2021 Q2 | -3.37 Million TWD | 52.19% |
| 2021 Q3 | -2.77 Million TWD | 18.02% |
| 2021 Q1 | -7.06 Million TWD | -109.63% |
| 2020 Q1 | 209 Thousand TWD | 101.72% |
| 2020 Q3 | -4.83 Million TWD | -108.05% |
| 2020 Q2 | 60.14 Million TWD | 28675.12% |
| 2020 FY | 134.41 Million TWD | 159.62% |
| 2020 Q4 | 73.39 Million TWD | 1616.78% |
| 2019 Q2 | 136 Thousand TWD | -36.45% |
| 2019 FY | -225.45 Million TWD | -2899.64% |
| 2019 Q1 | 214 Thousand TWD | 104.49% |
| 2019 Q3 | 217 Thousand TWD | 59.56% |
| 2019 Q4 | -12.11 Million TWD | -5684.79% |
| 2018 Q3 | 315 Thousand TWD | -4.26% |
| 2018 Q1 | 12.17 Million TWD | 121690.0% |
| 2018 FY | 8.05 Million TWD | 112.04% |
| 2018 Q4 | -4.77 Million TWD | -1614.29% |
| 2018 Q2 | 329 Thousand TWD | -97.3% |
| 2017 FY | -66.89 Million TWD | -242.35% |
| 2017 Q4 | 10 Thousand TWD | 0.0% |
| 2017 Q3 | - TWD | -100.0% |
| 2017 Q2 | 366 Thousand TWD | 0.0% |
| 2017 Q1 | - TWD | -100.0% |
| 2016 FY | 46.99 Million TWD | 240.57% |
| 2016 Q1 | - TWD | 0.0% |
| 2016 Q4 | 36 Thousand TWD | 0.0% |
| 2016 Q2 | 92.38 Million TWD | 0.0% |
| 2016 Q3 | - TWD | -100.0% |
| 2015 Q2 | - TWD | 0.0% |
| 2015 FY | -33.43 Million TWD | 0.0% |
| 2015 Q4 | - TWD | 0.0% |
| 2015 Q3 | - TWD | 0.0% |
| 2015 Q1 | - TWD | 0.0% |
| 2014 Q3 | - TWD | 0.0% |
| 2014 Q2 | - TWD | 0.0% |
| 2014 Q1 | - TWD | 0.0% |
| 2014 FY | - TWD | 0.0% |
| 2014 Q4 | - TWD | 0.0% |
| 2013 Q1 | - TWD | 0.0% |
| 2013 Q2 | - TWD | 0.0% |
| 2013 FY | - TWD | 0.0% |
| 2013 Q3 | - TWD | 0.0% |
| 2013 Q4 | - TWD | 0.0% |
| 2012 Q4 | - TWD | 0.0% |
| 2012 Q3 | - TWD | 0.0% |
| 2012 FY | - TWD | 0.0% |
| 2011 FY | - TWD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Anti-Microbial Savior BioteQ Co., Ltd | 329 Thousand TWD | 22439.514% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | 402.54 Million TWD | 118.258% |
| Level Biotechnology Inc. | 219.54 Million TWD | 133.477% |
| Sagittarius Life Science Corp | 71.47 Million TWD | 202.826% |
| NeoCore Technology Co., Ltd. | -9.08 Million TWD | -708.993% |
| TaiMed Biologics Inc. | 225.23 Million TWD | 132.632% |
| GlycoNex Incorporation | 995 Thousand TWD | 7486.633% |
| VBI | 16.42 Million TWD | 547.525% |
| GeneReach Biotechnology Corp. | 27.58 Million TWD | 366.448% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 198.45 Million TWD | 137.035% |
| SynCore Biotechnology Co.,Ltd | 521 Thousand TWD | 14206.91% |
| Genomics BioSci & Tech. Co.,Ltd. | 119.91 Million TWD | 161.293% |
| Visgeneer Inc. | 67.48 Million TWD | 208.913% |
| Mycenax Biotech Inc. | -375.19 Million TWD | 80.411% |
| Sunmax Biotechnology Co., Ltd. | 1.4 Billion TWD | 105.232% |
| G&E Herbal Biotechnology Co., Ltd. | 144.58 Million TWD | 150.832% |
| Neith Corporation | 18.01 Million TWD | 507.886% |
| Medigen Vaccine Biologics Corporation | 230.22 Million TWD | 131.924% |
| TaiwanJ Pharmaceuticals Co., Ltd. | 22.74 Million TWD | 423.177% |
| Enimmune corporation | -23.37 Million TWD | -214.453% |
| TaiRx, Inc. | 2.43 Million TWD | 3113.407% |
| CHO Pharma, Inc. | -28.27 Million TWD | -159.9% |
| EirGenix Inc. | 236.74 Million TWD | 131.045% |
| BioLASCO Taiwan Co., Ltd. | 104.35 Million TWD | 170.432% |
| Sunny Pharmtech Inc. | 285.52 Million TWD | 125.741% |
| Lin BioScience, Inc. | -17.92 Million TWD | -309.979% |
| BioGend Therapeutics Co., Ltd. | 89.61 Million TWD | 182.011% |
| Feng Chi Biotech Corp. | 80.72 Million TWD | 191.051% |
| Bio Preventive Medicine Corp. | 1.08 Million TWD | 6886.427% |
| Lukas Biomedical Inc. | 133.89 Million TWD | 154.894% |
| RBC Bioscience Corporation | 72.89 Million TWD | 200.826% |
| BiOptic Inc. | 152.74 Million TWD | 148.117% |
| BRIM Biotechnology, Inc. | 90 Thousand TWD | 81763.333% |
| Shine-On BioMedical Co.,Ltd. | 6.66 Million TWD | 1202.4% |
| Great Novel Therapeutics Biotech & Medicals | 2.61 Million TWD | 2910.593% |
| Syngen Biotech Co.,Ltd. | 643.91 Million TWD | 111.414% |
| Advagene Biopharma Co., Ltd. | -12 Million TWD | -512.373% |
| NaviFUS Corp. | 11.82 Million TWD | 721.434% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | 96.77 Million TWD | 175.947% |
| Sinew Pharma Inc. | -28.98 Million TWD | -153.569% |
| Andros Pharmaceuticals Co.,Ltd | 313 Thousand TWD | 23581.47% |
| Greenyn Biotechnology Co., Ltd | 392.45 Million TWD | 118.727% |
| Lumosa Therapeutics Co., Ltd. | 41.48 Million TWD | 277.182% |
| AP Biosciences Inc | 32.25 Million TWD | 327.876% |
| Medigen Biotechnology Corp. | 617.32 Million TWD | 111.906% |
| 3D Global Biotech Inc. | 5.27 Million TWD | 1493.572% |
| Pharmosa Biopharm Inc. | 314.5 Million TWD | 123.369% |
| Intech Biopharm Corporation | -163.99 Million TWD | 55.183% |
| Oneness Biotech Co., Ltd. | 32.56 Million TWD | 325.714% |
| Eusol Biotech Co.,Ltd. | -4.02 Million TWD | -1724.2% |
| TWi Biotechnology, Inc. | -9.73 Million TWD | -654.667% |
| Ever Supreme Bio Technology Co., Ltd | 484.75 Million TWD | 115.162% |
| TCI GENE Inc. | 174.61 Million TWD | 142.09% |
| MegaPro Biomedical Co., Ltd | -16.6 Million TWD | -342.726% |
| Senhwa Biosciences, Inc. | -10.17 Million TWD | -622.471% |
| Taiwan Bio Therapeutics Co., Ltd | 76.35 Million TWD | 196.252% |
| NatureWise Biotech & Medicals Corporation | 76.96 Million TWD | 195.497% |
| PharmaEngine, Inc. | 718.97 Million TWD | 110.223% |
| Savior Lifetec Corporation | 220.94 Million TWD | 133.264% |
| TaiGen Biopharmaceuticals Holdings Limited | 111.68 Million TWD | 165.807% |
| Meribank Biotech Co., Ltd | 138.87 Million TWD | 152.925% |
| Acepodia, Inc. | 16.59 Million TWD | 542.94% |
| Caliway Biopharmaceuticals Co., Ltd. | 27.46 Million TWD | 367.563% |